Popular
ANAB · Medicine & biotech · U.S.

AnaptysBio

Collects royalty payments on GSK’s cancer drug Jemperli.

Company Health

47
/100
Mixed
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $6 of every $100 in sales.
Is it growing?
25 of 25 · Good
Sales grew about 184% a year over the last 3 years.
Can it handle what it owes?
6 of 25 · Poor
It would take about 10 years of the cash its business brings in to pay off everything it owes.
Does it bring in spare cash?
16 of 25 · Okay
After paying for buildings and equipment, $8 of every $100 in sales was left as spare cash.

Who owns it

1 of 23 own it · 1 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From AnaptysBio’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $75.0 million in 2020 to $235 million in 2025, and it lost money every year.
2025
Sales
$235 million
Loss
$13.2 million

Spare cash each year

It had cash to spare in 1 of the 6 years, including $19.6 million in 2025.
2025
Spare cash
$19.6 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $364 million, including $138 million in cash, and owed $327 million.

Key facts

From its yearly report for 2025.
Sales
$235 million
Loss
$13.2 million
Spare cash
$19.6 million
Cash in the bank
$138 million
Everything it owes
$327 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-KT, filed Sep 21, 2026
Figures from AnaptysBio’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy